TITLE:
Study Evaluating Venlafaxine ER in Adults With Panic Disorder

CONDITION:
Panic Disorder

INTERVENTION:
Venlafaxine ER

SUMMARY:

      The primary objective of this study is to determine the efficacy, safety, and tolerability
      of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks
      in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase
      III study.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  A male or female outpatient

          -  Be at least 18 years of age and legal age of consent

          -  Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months
             before study day 1

        Exclusion Criteria:

          -  Treatment with venlafaxine (IR or ER) within 6 months of study day 1

          -  Known hypersensitivity to venlafaxine (IR or ER) or related compounds

          -  History or presence of any clinically important hepatic, renal, or other medical
             disease that might compromise the study or be detrimental to the patient (eg,
             clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
             cell epithelioma], uncontrolled hypertension)
      
